2.1.1.5: betaine-homocysteine S-methyltransferase
This is an abbreviated version!
For detailed information about betaine-homocysteine S-methyltransferase, go to the full flat file.
Word Map on EC 2.1.1.5
-
2.1.1.5
-
cystathionine
-
s-adenosylmethionine
-
choline
-
folate
-
remethylation
-
hyperhomocysteinemia
-
s-adenosylhomocysteine
-
adenosyltransferase
-
n-methyltransferase
-
one-carbon
-
beta-synthase
-
dimethylglycine
-
transsulfuration
-
methylenetetrahydrofolate
-
5-methyltetrahydrofolate-homocysteine
-
transmethylation
-
medicine
-
mthfd1
-
guanidinoacetate
-
homocysteine-induced
-
folate-dependent
-
homocystinuria
-
5-methyltetrahydrofolate
-
transcobalamin
-
b-vitamins
-
slc19a1
-
hypotaurine
-
molecular biology
-
analysis
-
nutrition
-
food industry
- 2.1.1.5
- cystathionine
- s-adenosylmethionine
- choline
- folate
-
remethylation
- hyperhomocysteinemia
- s-adenosylhomocysteine
-
adenosyltransferase
- n-methyltransferase
-
one-carbon
- beta-synthase
- dimethylglycine
-
transsulfuration
- methylenetetrahydrofolate
-
5-methyltetrahydrofolate-homocysteine
-
transmethylation
- medicine
- mthfd1
- guanidinoacetate
-
homocysteine-induced
-
folate-dependent
- homocystinuria
- 5-methyltetrahydrofolate
-
transcobalamin
-
b-vitamins
-
slc19a1
- hypotaurine
- molecular biology
- analysis
- nutrition
- food industry
Reaction
Synonyms
betaine homocysteine methyltransferase, betaine homocysteine methyltransferase-1, betaine homocysteine S-methyltransferase, betaine-homocysteine methyltransferase, betaine-homocysteine S-methyltransferase, betaine-homocysteine S-methyltransferase 2, betaine-homocysteine S-methyltransferase-2, betaine-homocysteine transmethylase, betaine:homocysteine methyltransferase, betaine:homocysteine S-methyltransferase, BHMT, BHMT-1, BHMT-2, BHMT1, BHMT2, methyltransferase, betaine-homocysteine
ECTree
2.1.1.5 betaine-homocysteine S-methyltransferaseAdvanced search results
results (
results (Inhibitors
Inhibitors on EC 2.1.1.5 - betaine-homocysteine S-methyltransferase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
INHIBITOR 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
(2S,11RS)-5-thia-2,11-diamino-8,8-dimethyldodecanedioic acid
-
more than 90% inhibition at 0.02 mM
(2S,11RS)-5-thia-2,11-diaminododecanedioic acid
-
about 60% inhibition at 0.02 mM
(2S,11S)-5,8-dithia-2,11-diaminododecanedioic acid
-
about 60% inhibition at 0.02 mM
(2S,5RS,8RS,11S)-5,8-dithia-2,11-diaminododecanedioic acid 5,8-dioxide
-
about 20% inhibition at 0.02 mM
(2S,8RS,11RS)-5-thia-2,11-diamino-8-methyldodecanedioic acid
-
competitive, more than 90% inhibition at 0.02 mM
(R,S)-2-(3-amino-3-carboxy-propylsulfanyl)-benzoic acid
-
ca. 43% inhibition at 0.02 mM
(R,S)-2-amino-4-(2-carboxy-ethyldisulfanyl)-butyric acid
-
ca. 30% inhibition at 0.02 mM
(R,S)-2-amino-4-(2-carboxymethylsulfanyl-ethylsulfanyl)-butyric acid
-
100% inhibition at 0.02 mM, very potent inhibitor and one of the strongest ever reported
(R,S)-2-amino-4-(2-carboxymethylsulfinyl-ethylsulfanyl)-butyric acid
-
ca. 90% inhibition at 0.02 mM
(R,S)-2-amino-4-(2-phosphonomethoxy-ethylsulfanyl)-butyrate
-
ca. 26% inhibition at 0.02 mM
(R,S)-2-amino-4-(3-carboxy-propylsulfanyl)-butyric acid
-
ca. 20% inhibition at 0.02 mM
(R,S)-2-amino-4-(4-carboxymethyl-benzylsulfanyl)-butyric acid
-
ca. 10% inhibition at 0.02 mM
(R,S)-2-amino-4-(4-phosphono-butylsulfanyl)-butyric acid
-
ca. 98% inhibition at 0.02 mM
(R,S)-2-amino-4-methylsulfanylmethylsulfanyl-butyric acid
-
ca. 21% inhibition at 0.02 mM
(R,S)-2-amino-4-[(phosphonomethyl-carbamoyl)-methylsulfanyl]-butyrate
-
ca. 9% inhibition at 0.02 mM
(R,S)-3-(3-amino-3-carboxy-propylsulfanyl)-benzoic acid
-
ca. 13% inhibition at 0.02 mM
(R,S)-4-(3-amino-3-carboxy-propylsulfanyl)-benzoic acid
-
ca. 99% inhibition at 0.02 mM
(R,S)-5-(3-amino-3-carboxy-propylsulfanyl)-pentanoic acid
-
100% inhibition at 0.02 mM, very potent inhibitor and one of the strongest ever reported, competitive inhibition with respect to betaine binding
(R,S)-5-(3-amino-3-carboxy-propylsulfinyl)-pentanoic acid
-
ca. 97% inhibition at 0.02 mM
(R,S)-5-(3-amino-3-carboxy-propylsulfonyl)-pentanoic acid
-
ca. 29% inhibition at 0.02 mM
(R,S)-6-(3-amino-3-carboxy-propylsulfanyl)-hexanoic acid
-
100% inhibition at 0.02 mM, very potent inhibitor and one of the strongest ever reported
(R,S,R,S)-2-amino-4-(2-amino-2-carboxy-ethylsulfinyl)-butyric acid
-
ca. 10% inhibition at 0.02 mM
(RS)-2-amino-4-[(2-carboxyethylthio)methylthio]butanoic acid
-
97.6% inhibition at 0.02 mM
(RS)-2-amino-4-[(3-carboxypropyl)disulfanyl]butanoic acid
-
19.1% inhibition at 0.02 mM
(RS)-2-amino-4-[2-(carboxymethylamino)ethylthio]butanoic acid
-
37.1% inhibition at 0.02 mM
(RS)-2-amino-4-[2-(R)-(1-carboxyethylamino)ethylthio]butanoic acid
-
15.5% inhibition at 0.02 mM
(RS)-2-amino-4-[2-(S)-(1-carboxyethylamino)ethylthio]butanoic acid
-
19.8% inhibition at 0.02 mM
(RS)-2-amino-4-[2-[(carboxymethyl)(methyl)amino]ethylthio]-butanoic acid
-
98.5% inhibition at 0.02 mM
(RS)-2-amino-4-[3-[(carboxymethyl)(methyl)amino]propylthio]butanoic acid
-
79.01% inhibition at 0.02 mM
(RS)-2-[[2-(3-amino-3-carboxypropylthio)ethyl]dimethylammonium]acetate
-
23.8% inhibition at 0.02 mM
(RS)-2-[[3-(3-amino-3-carboxypropylthio)propyl]dimethylammonio]acetate
-
3.3% inhibition at 0.02 mM
(RS)-5-(3-amino-3-carboxypropylselanyl)pentanoic acid
-
complete inhibition at 0.02 mM
(RS)-5-(3-amino-3-carboxypropylthio)-3,3-dimethylpentanoic acid
-
highly potent inhibitor of BHMT, complete inhibition at 0.02 mM
(RS)-5-(3-amino-3-carboxypropylthio)-3-methylpentanoic acid
-
highly potent inhibitor of BHMT, complete inhibition at 0.02 mM
5-[(3-amino-3-carboxypropyl)sulfanyl]pentanoic acid
-
complete inhibition at 0.02 mM
5-[3-(R,S)-3-amino-3-(hydroxyphosphorylpropyl)sulfanyl]-3,3-dimethylpentanoic acid
-
actinomycin D
leads to a decay of Bhmt mRNA, irrespective of the ambient osmolarity, at 120 min after addition, Bhmt mRNA levels are significantly decreased under hyperosmotic conditions, compared with the Bhmt mRNA levels found under the respective normo- or hypoosmotic condition
H2O2
causes a loss of catalytic Zn and a correlative loss of activity, irreversible
methyl methanethiosulfonate
causes a loss of catalytic Zn and a correlative loss of activity. Addition of beta-mercaptoethanol and exogenous Zn after methyl methanethiosulfonate treatment restores activity
S-(delta-carboxybutyl)-DL-homocysteine-sulfoxide
-
at 2 h after injection, there is a modest reduction in BHMT activity and a 90% increase in plasma total homocysteine
S-adenosyl-L-ethionine
-
irreversible, S-adenosyl-L-homocysteine and L-homocysteine prevent, but not DL-homocysteine, GSH, DTT or L-cysteine
S-adenosyl-L-homocysteine
-
non-linear/competitive to homocysteine, mixed/non-competitive to betaine
dimethylglycine
-
at 0.2 mM: 80% inhibition, at 2 mM: 97% inhibition; weak inhibitor, at 2 mM: 11% inhibition
dimethylglycine
-
at 0.25 mM: 64% inhibition, at 2.5 mM: 95% inhibition; weak inhibitor, at 2.5 mM: 19% inhibition
dimethylsulfonioacetate
-
at 2 mM: 79% inhibition; weak inhibitor, at 2 mM: 20% inhibition
dimethylsulfoniopropionate
-
weak inhibitor, at 2.5 mM: 11% inhibition; weak inhibitor, at 2.5 mM: 17% inhibition
S-(delta-Carboxybutyl)-DL-homocysteine
-
0.005 mM reduces BHMT activity ca. 95% in the standard assay that contains high levels (0.0025 mM) of L-homocysteine. Compared with saline-injected control mice, at 2 h postinjection, mice have 87% lower BHMT activity and a 2.7fold increase in plasma total homocysteine, effects that last nearly 8 h but return to normal by 24 h, level of BHMT protein remains constant over the 24-h period. After 6 injections (one every 12 h), the mice have 7fold higher plasma total homocysteine, a 65% reduction in the liver S-adenosylmethionine: S-adenosylhomocysteine ratio, and a marked upregulation of BHMT protein expression. When methionine is injected, postmethionine load plasma total homocysteine levels are 2.2fold higher at 2 h postinjection
S-(delta-carboxybutyl)-L-homocysteine
-
at 0.05 mM: 97% inhibition, at 0.5 mM: total inhibition; weak inhibitor, at 0.5 mM: 26% inhibition
S-(delta-carboxybutyl)-L-homocysteine
-
at 0.025 mM: 22% inhibition, at 0.0625 mM: 36% inhibition, at 0.125 mM: 49% inhibition, at 0.5 mM: 81% inhibition; total inhibition
S-adenosyl-L-methionine
-
irreversible, S-adenosyl-L-homocysteine and L-homocysteine prevent, not DL-homocysteine, GSH, DTT or L-cysteine
additional information
-
hypertonicity induces a decrease in BHMT mRNA and protein levels in liver and kidney
-
additional information
-
not inhibitory: methionine or ethionine; product inhibition
-
additional information
-
no inhibition by sarcosine; not inhibitory: S-(gamma-carboxypropyl)-DL-homocysteine, S-(beta-carboxyethyl)-DL-homocysteine
-
additional information
-
no inhibition by Ac-Val-DL-Ala-psi[(PO2-)-CH2]-DL-Leu-Cys-NH2, Ac-DL-Ala-psi[(PO2-)-CH2]-DL-Leu-NH2, Ac-Val-DL-Ala-psi[(PO2-)-CH2]-DL-Leu-His
-
additional information
S-adenosylmethionine decreases BHMT mRNA levels in dose- and time-dependent manner, down-regulates BHMT expression in part by inducing nuclear factor kappaB, which acts as a repressor for the human BHMT gene, the inhibitor is nuclear factor kappaB dependent. 5'-methylthioadenosine decreases BHMT mRNA levels in dose- and time-dependent manner, down-regulates BHMT expression in part by inducing nuclear factor kappaB, which acts as a repressor for the human BHMT gene, the inhibitor has nuclear factor kappaB dependent and -independent mechanisms
-
additional information
-
S-adenosylmethionine decreases BHMT mRNA levels in dose- and time-dependent manner, down-regulates BHMT expression in part by inducing nuclear factor kappaB, which acts as a repressor for the human BHMT gene, the inhibitor is nuclear factor kappaB dependent. 5'-methylthioadenosine decreases BHMT mRNA levels in dose- and time-dependent manner, down-regulates BHMT expression in part by inducing nuclear factor kappaB, which acts as a repressor for the human BHMT gene, the inhibitor has nuclear factor kappaB dependent and -independent mechanisms
-
additional information
-
not inhibited by (R)-5-(2-amino-2-carboxy-ethylsulfanyl)-pentanoic acid, (R,S)-4-allylsulfanyl-2-amino-butyric acid and (R,S)-2-amino-4-[(phosphonomethyl-carbamoyl)-methylsulfanyl]-butyric acid ester
-
additional information
-
not inhibited by (RS)-2-[[(3-amino-3-carboxypropylthio)methyl]dimethylammonium] acetate and (RS)-2-amino-4-[2-(2-carboxyethylamino)ethylthio]butanoic acid
-
additional information
-
not inhibitory: taurine, cysteic acid, cysteine sulfinate, sulfate, glycine, L-serine, L-threonine; product inhibition
-
additional information
-
insulin decreases the abundance of BHMT mRNA and the rate of de novo mRNA transcription of the gene in H4IIE cells, plays a direct role in the regulation of BHMT transcription
-
additional information
-
hyperosmotic NaCl, hyperosmotic raffinose but not hyperosmotic urea suppresses Bhmt mRNA expression, suggesting that cell shrinkage rather than increased ionic strength or hyperosmolarity per se is the trigger, osmosensitivity of Bhmt mRNA expression is impaired by inhibitors of tyrosine kinases and cyclic nucleotide-dependent kinases
-
additional information
hyperosmotic NaCl, hyperosmotic raffinose but not hyperosmotic urea suppresses Bhmt mRNA expression, suggesting that cell shrinkage rather than increased ionic strength or hyperosmolarity per se is the trigger, osmosensitivity of Bhmt mRNA expression is impaired by inhibitors of tyrosine kinases and cyclic nucleotide-dependent kinases
-
